Dr. Carolyn M. Klinge
by Michael R. Hicks — last modified Oct 16, 2012 02:56 PM
Email Dr. Carolyn M. Klinge
Address: 580 S. Preston St., Delia Baxter (Baxter II) Building, Room 221E
B.A., 1979, Keuka College
Molecular Mechanisms of Estrogen Action
Mechanisms of Endocrine Resistance in Breast Cancer
Estrogens in Lung Adenocarcinoma
Transcriptional Regulation of Gene Expression Including miRNA Expression
Dr. Klinge’s research focuses on the molecular mechanisms by which estrogens regulate physiological functions in different cell types including breast and endometrial cancer, lung adenocarcinoma, and the vascular endothelium. The primary focus of the lab is to determine how estrogens regulate the expression of specific genes and microRNAs in a cell-type and promoter context-specific manner. Estrogens bind two different estrogen receptor proteins (ER) in the cell nucleus: ER? and ER?. In her main NIH-funded project, Dr. Klinge and members of her lab group are addressing how estrogens regulate nuclear-mitochondrial signaling by genomic and non-genomic mechanisms and the role of miRNAs in mediating estrogenic signaling in breast cancer cells. The goal of a second NIH-funded project is to determine the role of aberrant microRNA expression in endocrine- resistant breast cancer. Another project is addressing the role of COUP-TFII in antiestrogen-sensitivity and the mechanism for the decrease in COUP-TFII expression in endocrine-resistant breast cancer. A fourth project is supported by a grant from Joan’s Legacy and the Lungevity Foundations. In that work, Dr. Klinge and her group are examining the mechanisms accounting the gender disparity in lung adenocarcinoma and the role of coregulators and ER?-interacting proteins in this process. In a fifth project, supported by the American Heart Association, Dr. Klinge is examining how estradiol and the dietary chemical resveratrol, which is enriched in red wine, mediate cardioprotective effects in vascular endothelium. This project is examining intracellular mechanisms of estrogen action that are independent of nuclear ER activity. Two collaborative research projects are aimed at determining the anti-cancer activity of anacardic acid and the role of estrogen receptor signaling in thyroid cancer.
Mattingly, K.A. and Klinge, C.M. Diesel Exhaust Particle Extracts Inhibit Transcription of Nuclear Respiratory Factor-1 and Cell Viability in Human Umbilical Vein Endothelial Cells Archives of Toxicology 86: 633-42, 2012. PMID:22105178
Klinge CM. Inhibition of non-small-cell lung cancer growth by combined fulvestrant and vande Future Oncol. 2012 May;8(5):529-33, PMID:22646768
Klinge, C.M. miRNAs and estrogen action. Trends in Endocrinology and Metabolism 23: 223-33, 2012 PMID:22503553
Nweze, I.C., Smith, J.W., Zhang, B., Lakshmanan, J., Klinge, C.M., and Harbrecht, B.G. 17-Estradiol attenuates cytokine-induced nitric oxide production in rat hepatocytes. J. Trauma Acute Care Surg. 73: 408-12, 2012. PMID:22846947
Litchfield, L.M., Riggs, K.A., Hockenberry, A.M., Oliver, L.D., Barnhart, K.G., Fox, J.M., Cai, J, Pierce, W.M.,Jr., Ivanova, M.M., Bates, P.J, Datta, S., Appana, S.N., Kulesza, P., McBryan, J., Young, L.S., and Klinge, C.M. Nucleolin enhances COUP-TFII activation of retinoic acid receptor beta transcription in breast cancer cells. PLoS ONE 7 (5) e38278, 2012. Epub 2012 May 31, PMID:22693611
Litchfield, L.M. and Klinge, C.M. Multiple roles of COUP-TFII in cancer initiation and progression' J. Mol. Endocrinol., in press, 2012, ms #JME-12-0144 PMID:22966133
Teng, Y., Manavalan, T.T., Hu, C., Medjakovic, S., Jungbauer, A., and Klinge, C.M. Endocrine Disruptors Fludioxonil and Fenhexamid Stimulate miR-21 Expression in Breast Cancer Cells. Toxicological Sciences, in press, 2012, # TOXSCI-12-0551-R1.
Mattingly KA, Klinge CM. Diesel exhaust particulate extracts inhibit transcription of nuclear respiratory factor-1 and cell viability in human umbilical vein endothelial cells. Arch Toxicol. 2011 Nov 22. [Epub ahead of print] PMID:22105178
Manavalan TT, Teng Y, Appana SN, Datta S, Kalbfleisch TS, Li Y, Klinge CM. Differential expression of microRNA expression in tamoxifen-sensitive MCF-7 versus tamoxifen-resistant LY2 human breast cancer cells. Cancer Lett. 2011 Dec 26;313(1):26-43. Epub 2011 Sep 10. PMID: 21955614
Ivanova M, Abner S, Pierce W Jr, Klinge C. Ligand-dependent differences in estrogen receptor beta-interacting proteins identified in lung adenocarcinoma cells corresponds to estrogenic responses. Proteome Sci. 2011 Sep 27;9(1):60. PMID: 21951318
Klinge CM, Radde BN, Imbert-Fernandez Y, Teng Y, Ivanova MM, Abner SM, Martin AL. Targeting the Intracellular MUC1 C-terminal Domain Inhibits Proliferation and Estrogen Receptor Transcriptional Activity in Lung Adenocarcinoma Cells. Mol Cancer Ther. 2011 Nov;10(11):2062-71. Epub 2011 Aug 23. PMID: 21862684
Imbert-Fernandez Y, Radde BN, Teng Y, Young WW Jr, Hu C, Klinge CM. MUC1/A and MUC1/B splice variants differentially regulate inflammatory cytokine expression. Exp Eye Res. 2011 Nov;93(5):649-57. Epub 2011 Aug 16. PMID: 21854773
Porter AM, Klinge CM, Gobin AS. Covalently grafted VEGF165 in hydrogel models upregulates the cellular pathways associated with angiogenesis. Am J Physiol Cell Physiol. 2011 Nov;301(5):C1086-92. Epub 2011 Jul 27. PMID: 21795519
Ivanova MM, Luken KH, Zimmer AS, Lenzo FL, Smith RJ, Arteel MW, Kollenberg TJ, Mattingly KA, Klinge CM. Tamoxifen increases nuclear respiratory factor 1 transcription by activating estrogen receptor beta and AP-1 recruitment to adjacent promoter binding sites. FASEB J. 2011 Apr;25(4):1402-16. Epub 2011 Jan 13. PMID: 21233487
Porter AM, Klinge CM, Gobin AS. Biomimetic hydrogels with VEGF induce angiogenic processes in both hUVEC and hMEC. Biomacromolecules. 2011 Jan 10;12(1):242-6. Epub 2010 Dec 3. PMID: 21128597
Schultz, D.J., Wickramasinghe, N.S., Ivanova, M.M., Isaacs, S.M., Riggs, K.A., Dougherty, S.M., Imbert, Y., Chen, C., Mattingly, K.A., and Klinge, C.M. Anacardic acid inhibits breast cancer cell proliferation by inhibition of estrogen receptor- estrogen response element binding and gene transcription. Mol Cancer Ther. 9:594-605, 2010. Epub 2010 Mar 2. PMID: 20197399
Ivanova, M.M., Mazhawidza, W., Dougherty, S.M., and Klinge, C.M. Sex differences in estrogen receptor subcellular location and activity in lung adenocarcinoma cells. American Journal of Respiratory Cell and Molecular Biology 42: 320-330, 2010. Epub 2009 Jun 25. PMID: 19556604 PMCID: PMC2830404
Kumar, A. *, Klinge, C.M. *, and Goldstein, R.E. Estradiol-induced proliferation of papillary and follicular thyroid cancer cells is mediated by estrogen receptors alpha and beta. Int. J. Oncol. 36: 1067-1080, 2010. *AK and CMK are equal first authors. CMK is the corresponding author. PMID: 20372779
Klinge, C.M., Riggs, K.A., Wickramasinghe, N.S., McConda, D.B., and Barry, P.N. Estrogen receptor alpha 46 is reduced in tamoxifen resistant breast cancer cells and re-expression inhibits cell proliferation and estrogen receptor alpha 66-regulated target gene transcription. Mol. Cell. Endocrinol. 323: 268-276, 2010.
Wickramasinghe, N.S., Manavalan, T.T., Dougherty, S.M., Riggs, K.A., Li, Y., and Klinge, C.M. Estradiol downregulates miR-21 expression and increases miR-21 target gene expression in MCF-7 breast cancer cells. Nucleic Acids Res. 37: 2584-2595, 2009.
Ivanova, M.M., Mazhawidza, W., Dougherty, S.M., Minna, J.D. and Klinge, C.M. Activity and intracellular location of estrogen receptors alpha and beta in human bronchial epithelial cells (HBECs). Mol. Cell. Endocrinol. 305:12-21, 2009.
Sanada, N., Gotoh, Y., Shimazaw, R., Klinge, C.M., and Kizu, R. Repression of activated aryl hydrocarbon receptor-induced transcriptional activation by 5?-dihydrotestosterone in human prostate cancer LNCaP and human breast cancer T47D cells. J. Pharmacol. Sci.109: 380-387, 2009.
Klinge, C.M. Estrogen regulation of microRNA expression. Current Genomics 10: 169-183, 2009.
Thomas E. Geoghegan
Russell A. Prough
Christine Schaner Tooley
James L. Wittliff